Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Axial Therapeutics to Present at Upcoming Conferences
Posted: January 6, 2024 at 2:37 am
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, PhD, Chief Executive Officer, will participate in the following upcoming conferences:
Posted in Global News Feed
Comments Off on Axial Therapeutics to Present at Upcoming Conferences
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Posted: January 6, 2024 at 2:37 am
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”). An aggregate of 7,091,993 units of the Company (each a “Unit”) were issued and sold under the Private Placement at a price of CAD$0.28 per Unit for aggregate proceeds of CAD$1,985,758.04.
Follow this link:
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Posted in Global News Feed
Comments Off on NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Posted: January 6, 2024 at 2:37 am
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
Read this article:
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Posted in Global News Feed
Comments Off on Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…
Posted: January 6, 2024 at 2:37 am
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
Originally posted here:
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,...
Posted in Global News Feed
Comments Off on SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Posted: January 6, 2024 at 2:37 am
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively
Read the rest here:
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Posted in Global News Feed
Comments Off on Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T…
Posted: January 6, 2024 at 2:37 am
Expect to disclose initial SC262 clinical data in 2024 Expect to disclose initial SC262 clinical data in 2024
Posted in Global News Feed
Comments Off on Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T…
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Posted: January 6, 2024 at 2:37 am
AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW.
Read this article:
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Posted in Global News Feed
Comments Off on Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
Posted: January 6, 2024 at 2:37 am
Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States. The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world. The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.
Originally posted here:
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
Posted in Global News Feed
Comments Off on Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Posted: January 6, 2024 at 2:37 am
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
Link:
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Posted in Global News Feed
Comments Off on Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
